CBL mutation
|
MDS
|
CBL mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
CBL mutation
|
AML
|
CBL mutation
|
AML
|
gilteritinib Resistant: B - Late Trials
|
gilteritinib Resistant: B - Late Trials
|
CBL mutation
|
MDS
|
CBL mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
quizartinib Sensitive: C2 – Inclusion Criteria
|
CBL mutation
|
AML
|
CBL mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
CBL mutation
|
Sarcoma
|
CBL mutation
|
Sarcoma
|
MGCD516 Sensitive: C3 – Early Trials
|
MGCD516 Sensitive: C3 – Early Trials
|
CBL mutation
|
NSCLC
|
CBL mutation
|
NSCLC
|
MGCD516 Sensitive: C3 – Early Trials
|
MGCD516 Sensitive: C3 – Early Trials
|
CBL mutation
|
Melanoma
|
CBL mutation
|
Melanoma
|
MGCD516 Sensitive: C3 – Early Trials
|
MGCD516 Sensitive: C3 – Early Trials
|
CBL mutation
|
NSCLC
|
CBL mutation
|
NSCLC
|
SU11274 Sensitive: D – Preclinical
|
SU11274 Sensitive: D – Preclinical
|
CBL mutation
|
CMML
|
CBL mutation
|
CMML
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|